The Effects of Ferric Derisomaltose Administered Before Hospital Discharge in Stabilised Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life: a Randomised, Parallel-group, Double-blind, Placebo Controlled Trial (COREVIVE-HFrEF)
Latest Information Update: 10 Aug 2023
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms COREVIVE-HFrEF
Most Recent Events
- 05 Aug 2023 Status changed from not yet recruiting to recruiting.
- 04 Aug 2023 New trial record